E Fund Hang Seng SCHK Innovative Drug ETF(159316.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
E Fund Hang Seng SCHK Innovative Drug ETF
159316.SZ
News
View More

"Large Firms" China Merchants Securities initiates coverage on Kanion Pharmaceutical, expects the impact of centralized procurement to be digested

China Merchants Securities has initiated coverage on Kanion Pharmaceutical, expecting net profits of RMB 1.65 billion, RMB 1.96 billion, and RMB 2.27 billion for the years 2025 to 2027, with annual growth rates of 1.5%, 18.9%, and 15.8%, respectively. The report indicates that Kanion Pharmaceutical has absorbed the impact of centralized procurement and has transformed into a full-chain innovative pharmaceutical company. Although there will be short-term performance fluctuations, the launch of innovative products starting in 2024 is expected to bring a turning point in performance. The company focuses on specialties and operates independently in skin health, ophthalmology, and Southeast Asian markets

AASTOCKS·
SZ
159316
+1.59%
SH
520880
+1.53%
SH
520690
+1.06%
AASTOCKS·
SZ
159316
+1.59%
SH
520880
+1.53%
SH
520690
+1.06%

Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally.

Insilico Medicine and Hygtia Therapeutics, a start-up supported by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have recently formed an exclusive partnership to further develop ISM8969 on a global scale. This collaboration involves a shared 50% ownership of worldwide rights between the two companies.

Unusual Whales·
SZ
159506
+1.54%
SZ
159316
+1.59%
SH
513120
+1.30%
Unusual Whales·
SZ
159506
+1.54%
SZ
159316
+1.59%
SH
513120
+1.30%

RemeGen Co. Ltd. completes share buyback totaling 194,144 shares for RMB20,004,012

RemeGen Co. Ltd. has completed its first share buyback, repurchasing 194,144 shares on the Shanghai Stock Exchange for approximately RMB20,004,012. The shares were bought at prices ranging from RMB102.17 to RMB103.78. The buyback was funded through the company's own or self-raised funds and will not impact its business activities, financial condition, or listing status.

Reuters·
SH
520880
+1.53%
SH
520690
+1.06%
SZ
159316
+1.59%
Reuters·
SH
520880
+1.53%
SH
520690
+1.06%
SZ
159316
+1.59%

Extrawell Pharmaceutical Appoints Yang Xiaorong as Independent Non-Executive Director

Extrawell Pharmaceutical Holdings Ltd. has announced the resignation of Mr. Fang Lin Hu as Independent Non-Executive Director, effective January 20, 2026. Ms. Yang Xiaorong has been appointed as the new Independent Non-Executive Director and committee member, while Ms. Jin Song will chair the Audit and Remuneration Committees.

Reuters·
SZ
159506
+1.54%
SH
520690
+1.06%
SZ
159316
+1.59%
Reuters·
SZ
159506
+1.54%
SH
520690
+1.06%
SZ
159316
+1.59%

Finnish M&A deal value rose 20% despite unchanged transaction volumes: Carner Corporate Finance

In 2025, Finland's M&A market saw a 20% increase in total deal value, rising to EUR 12.5 billion, despite transaction volumes remaining stable at 579 deals. Investors became more selective, focusing on strategic assets in infrastructure and healthcare. Notable transactions included Hellman & Friedman's investment in Mehiläinen and the divestment of Tietoevry's Tech Services. The challenging macroeconomic environment, with GDP growth between 0.2% and 0.5% and unemployment over 10%, influenced buyer selectivity. Carner Corporate Finance views 2025 as a transitional year, setting the stage for future recovery in the M&A landscape.

fidelity·
SH
520690
+1.06%
SZ
159506
+1.54%
SH
520880
+1.53%
fidelity·
SH
520690
+1.06%
SZ
159506
+1.54%
SH
520880
+1.53%
© 2026 Longbridge｜Disclaimer